LabCorp Announces Launch of New Companion Diagnostic for Non-Small Cell Lung Cancer

The Roche cobas ® EGFR Mutation Test v2 is the First Blood-Based Liquid Biopsy Test Approved by FDA for Clinical Use BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 27, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today the availability of a new application for the

LabCorp is Scheduled to Present at the 36th Annual William Blair Growth Stock Conference

BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 8, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced it will participate at the 36 th Annual William Blair Growth Stock Conference . LabCorp’s presentation is planned for Tuesday, June 14, 2016 at 3:50 PM (ET) .

LabCorp Announces the Availability of the RealStar® Zika Virus Test

altona Diagnostics’ RealStar ® Zika Virus RT-PCR Kit U.S. Has Received FDA Emergency Use Authorization BURLINGTON, N.C. --(BUSINESS WIRE)--Jun. 6, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) today announced the nationwide availability of testing for Zika virus using

One Year After Launch, BRCA Share™ Open Data Initiative Reveals New Findings on BRCA Gene Mutations Linked to Hereditary Breast and Ovarian Cancer Risk

Co-Founded by Quest Diagnostics and Inserm, with LabCorp as First Member, BRCA Share is now the Largest Open BRCA Datashare of Curated BRCA Variants Clinically Suitable for Patient Management MADISON, N.J., PARIS, France, BURLINGTON, N.C. – June 1, 2016 – BRCA Share, a public-private BRCA gene

New Complementary Diagnostic Test Available from LabCorp for Treatment of Bladder Cancer

VENTANA PD-L1 (SP142) Assay Identifies Metastatic Patients with Urothelial Cancer that May Benefit from Treatment with TECENTRIQ ® (atezolizumab) BURLINGTON, N.C. --(BUSINESS WIRE)--May 19, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) today announced the nationwide

LabCorp Announces the Launch of the Epi proColon® Test for Colorectal Cancer Screening

First FDA-Approved Blood-Based Colorectal Cancer Test Offers Alternative for Patients Non-Compliant with Existing Screening Options BURLINGTON, N.C. --(BUSINESS WIRE)--May 9, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced the launch of Epi proColon ® , a

LabCorp to Webcast Its Annual Meeting of Stockholders

BURLINGTON, N.C. --(BUSINESS WIRE)--May 6, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) today announced that its Annual Meeting of Stockholders will be webcast live beginning May 11, 2016 at 9:00 a.m. Eastern Daylight Time via the Company website at www.labcorp.com .

Laboratory Corporation of America® Holdings Announces 2016 First Quarter Results and Raises 2016 Guidance

Q1 Net revenue of $2.3 billion , up 30% over last year Q1 Diluted EPS of $1.55 ; Q1 Adjusted EPS of $2.02 , up 15% over last year 2016 Adjusted EPS guidance raised to $8.55 – $8.95 , up 8% to 13% over 2015 BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 25, 2016-- Laboratory Corporation of America ®

LabCorp Hires Jonathan Zung as Group President of Clinical Development and Commercialization Services for Covance Drug Development

BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 11, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE:LH) today announced that Jonathan Zung , Ph.D., has been named group president, Clinical Development & Commercialization Services for Covance Drug Development, effective April 5,

Conversion Right Triggered for Labcorp’s Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C. --(BUSINESS WIRE)--Apr. 4, 2016-- Laboratory Corporation of America ® Holdings (LabCorp ® ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.